Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 166.66% | 1,250.59% | 1,292.26% | -35.58% | 11.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 166.66% | 1,250.59% | 1,292.26% | -35.58% | 11.14% |
| Cost of Revenue | 582.24% | -16.35% | 149.56% | -51.02% | -25.39% |
| Gross Profit | -877.62% | 90.16% | 225.00% | 61.03% | 39.52% |
| SG&A Expenses | 950.79% | -8.30% | -15.95% | 47.04% | 27.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 724.68% | -13.14% | 78.35% | -20.86% | -11.13% |
| Operating Income | -915.58% | 56.39% | 120.33% | 15.35% | 16.84% |
| Income Before Tax | -1,704.61% | 57.75% | 121.96% | 14.00% | 16.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,704.61% | 57.75% | 116.69% | 14.00% | 16.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,704.61% | 57.75% | 116.69% | 14.00% | 16.61% |
| EBIT | -915.58% | 56.39% | 120.33% | 15.35% | 16.84% |
| EBITDA | -926.93% | 60.67% | 127.66% | 15.29% | 17.00% |
| EPS Basic | -805.60% | 78.25% | 111.47% | 56.32% | 56.17% |
| Normalized Basic EPS | -805.61% | 78.21% | 114.95% | 57.10% | 56.17% |
| EPS Diluted | -805.60% | 78.25% | 111.21% | 56.32% | 56.17% |
| Normalized Diluted EPS | -805.61% | 78.21% | 114.62% | 57.10% | 56.17% |
| Average Basic Shares Outstanding | 99.27% | 94.23% | 45.46% | 96.89% | 90.25% |
| Average Diluted Shares Outstanding | 99.27% | 94.23% | 48.86% | 96.89% | 90.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |